Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy

Leukemia and Lymphoma

Volumn 55, Issue 7, 2014, Pages 1533-1537

  Bhatnagar, Bhavana ^a,b   Duong, Vu H ^a,b   Gourdin, Theodore S ^a,b   Tidwell, Michael L ^a   Chen, Ching ^a,b   Ning, Yi ^a,b   Emadi, Ashkan ^a,b   Sausville, Edward A ^a,b   Baer, Maria R ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Decitabine; Demethylating agents; Elderly

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; HYDROXYUREA; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DECITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLAST CELL; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FEBRILE NEUTROPENIA; FEMALE; FUNGEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA REMISSION; LUNG MYCOSIS; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SKIN INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; REMISSION; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903463772     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.856425     Document Type: Article

References (22)

1. Appelbaum F R, Gundacker H, Head D R, et al. Age and acutemyeloid leukemia. Blood 2006 ; 107 : 3481-3485.
2. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloidleukemia: real world data on decision to treat and outcomes from theSwedish Acute Leukemia Registry. Blood 2009 ; 113 : 4179-4187.
3. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetictherapy is associated with similar survival compared with intensivechemotherapy in older patients with newly diagnosed acute myeloidleukemia. Blood 2012 ; 120 : 4840-4845.
4. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improvespatient outcomes in myelodysplastic syndromes: results of a phase IIIrandomized study. Cancer 2006 ; 106 : 1794-1803.
5. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomizedstudy of 3 schedules of low-dose decitabine in higher-riskmyelodysplastic syndrome and chronic myelomonocytic leukemia.Blood 2007 ; 109 : 52-57.
6. Steensma D P, Baer M R, Slack J L, et al. Multicenter study ofdecitabine administered daily for 5 days every 4 weeks to adults withmyelodysplastic syndromes: the alternative dosing for outpatienttreatment (ADOPT) trial. J Clin Oncol 2009 ; 27 : 3842-3848.
7. Blum W, Klisovic R B, Hackanson B, et al. Phase I study of decitabinealone or in combination with valproic acid in acute myeloid leukemia.J Clin Oncol 2007 ; 25 : 3884-3891.
8. Cashen AF, Schiller GJ, O ' Donnell MR, et al. Multicenter, phase IIstudy of decitabine for the fi rst-line treatment of older patients withacute myeloid leukemia. J Clin Oncol 2010 ; 28 : 556-561.
9. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive signifi cance in older AML patients treated with a 10-dayschedule of decitabine. Proc Natl Acad Sci USA 2010 ; 107 : 7473-7478.
10. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patientchoice, with physician advice, of either supportive care or low-dosecytarabine for the treatment of older patients with newly diagnosedacute myeloid leukemia. J Clin Oncol 2012 ; 30 : 2670-2677.
11. Lubbert M, Ruter BH, Claus R, et al. Amulticenter phase II trial ofdecitabine as fi rst-line treatment for older patients with acute myeloidleukemia judged unfi t for induction chemotherapy. Haematologica2012 ; 97 : 393-401.
12. Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patientswith newly diagnosed and relapsed acute myeloid leukemia. LeukLymphoma 2013; 54: 2003-2007.
13. Vardiman J, Catovsky D, Flandrin G R, et al. Fourth InternationalWorkshop on Chromosomes in Leukemia 1982: correlation betweenmorphology and karyotype. Cancer Genet Cytogenet 1984 ; 11 : 275-281.
14. Dohner H, Estey EH, Amadori S, et al. Diagnosis and managementof acute myeloid leukemia in adults: recommendations from aninternational expert panel, on behalf of the European LeukemiaNet.Blood 2010 ; 115 : 453-474.
15. Grimwade D, Hills RK, Moorman AV, et al.; National CancerResearch Institute Adult Leukaemia Working Group. Refi nement ofcytogenetic classifi cation in acute myeloid leukemia: determination ofprognostic signifi cance of rare recurring chromosomal abnormalitiesamong 5876 younger adult patients treated in the United KingdomMedical Research Council trials. Blood 2010; 116: 354-365.
16. Allen PB, Koka R, Kleinberg ME, et al. Scedosporiumapiospermum soft tissue infection as the initial presentation of acutemyeloid leukemia: a case report. J Clin Oncol 2013 ; 31 : e98-e100.
17. Cheson B D. Clinical application and proposal for modifi cationof the International Working Group (IWG) response criteria inmyelodysplasia. Blood 2006 ; 108 : 419-425.
18. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendationsof the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, andReporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.J Clin Oncol 2003 ; 21 : 4642-4649.
19. Yan P, Frankhouser D, Murphy M, et al. Genome-wide methylationprofi ling in decitabine-treated patients with acute myeloid leukemia.Blood 2012 ; 120 : 2466-2474.
20. Claus R, Pfeifer D, Almstedt M, et al. Decitabine induces veryearly in vivo DNA methylation changes in blasts from patients withacute myeloid leukemia. Leuk Res 2013; 37: 190-196.
21. Klco J M, Spencer D H, Lamprecht T L, et al. Genomic impact oftransient low-dose decitabine treatment on primary AML cells. Blood2013 ; 121 : 1633-1643.
22. Fandy T E, Herman J G, Kerns P, et al. Early epigenetic changesand DNA damage do not predict clinical response in an overlappingschedule of 5-azacytidine and entinostat in patients with myeloidmalignancies. Blood 2009 ; 114 : 2764-2773.